Noven Gets Tentative FDA OK for Stavzor
(December 26, 2007) Noven Pharmaceuticals Inc. said Wednesday the Food
and Drug Administration tentatively approved its drug Stavzor for the
treatment of
manic episodes associated with
bipolar disorder, epilepsy and migraine headaches.
"Tentative approval" generally means the FDA has concluded a drug product
has met all required quality, safety and effectiveness standards, but
because of existing patents and/or exclusivity rights, it cannot yet be
marketed in the United States.
Noven said the application for Stavzor refers to Abbott Laboratories'
drug
Depakote, which is approved for bipolar disorder, epilepsy and
migraines. Both products include a key ingredient called
valproic acid.
If approved for marketing, however, Stavzor would be a branded rival, not
a generic substitute for Depakote, Noven said.
Noven said based on the tentative approval letter and its understanding
of Depakote's expiration of exclusivity, Noven continues to expect final FDA
approval of Stavzor by the end of July 2008.
Wednesday's letter comes after the FDA in October issued an approvable
letter for Stavzor asking for certain non-clinical information as a
condition to final approval.
Noven acquired a license to market and sell Stavzor in the U.S., as part
of Noven's acquisition of JDS Pharmaceuticals in August. The application for
Stavzor was submitted to the FDA by High Point, Calif.-based Banner
Pharmacaps Inc., which developed the product.
Source: The Associated Press
Last updated: 12/07
Related Information:
back to
top ~ bipolar news index~
send page to a
friend |